Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certification & Accreditation
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Features
AMS Features
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry
By
- AMS
posted
Feb 28, 2020 08:02 AM
0
Recommend
Volume 32, Issue 8
, December 2021, Page 907-915
.
0 comments
0 views
Related Content
Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis
- AMS
Added Apr 01, 2020
Blog Entry
Therapeutic outcomes of pemphigus in a referral service in Northern Brazil: a retrospective study of 32 patients
- AMS
Added Jan 24, 2020
Blog Entry
Correct performance of subcutaneous injections in plaque psoriasis: comparison of trained and untrained patients with different application systems in routine clinical care
- AMS
Added Feb 03, 2020
Blog Entry
Impact of lifestyle and demographics on the gut microbiota of acne patients and the response to minocycline
- AMS
Added Feb 05, 2020
Blog Entry
Should the presence of psoriatic arthritis change how we manage psoriasis?
- AMS
Added Nov 26, 2021
Blog Entry
Permalink
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic